IP Library › Granted Patent US 12,397,086
Granted Patent B2
US 12,397,086 · App. 15/588,331 · Granted Aug 26, 2025

Methods of modulating bone remodeling

Inventors: Scheffer Tseng (Pinecrest, FL); Ek Kia Tan (Miami, FL); Hua He (Miami, FL)
Assignee: BIOTISSUE HOLDINGS INC.
A61L27/365A61K9/0019A61K31/728A61K33/06A61K35/50A61K35/51A61K35/54A61K38/57A61L27/20A61L27/26A61L27/34A61L27/3604A61L27/3847A61L27/54A61L2300/236A61L2300/252A61L2300/434A61L2300/45A61L2300/606A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,397,086
App. No.
15/588,331
Granted
Aug 26, 2025
Kind
B2
Abstract

Disclosed herein, in certain instances, are methods of inhibiting osteoclast differentiation, bone resorption, bone formation, and bone remodeling in an individual in need thereof, comprising administering to the individual a composition comprising substantially fetal support tissue product including amniotic membrane and umbilical cord or an extract thereof, or a composition comprising substantially isolated HC-HA complex.

Claims (21)

1. A bone implant comprising a fetal support tissue product comprising umbilical cord amniotic membrane (UCAM) or an extract thereof, wherein the UCAM or the extract thereof is cryopreserved, lyophilized, terminally sterilized, or a combination thereof, wherein the UCAM or an extract thereof does not comprise placental amniotic membrane; and wherein the UCAM or the extract thereof comprises at least 0.08 μg/ml heavy chain (HC) of inter-alpha-inhibitor (IαI), hyaluronan (HA), and PTX3 (HC-HA/PTX3) complex, wherein the bone implant inhibits osteoclast formation.

2. The bone implant of claim 1 , wherein UCAM or the extract thereof comprises at least 25.0 μg/ml of HC-HA/PTX3 complex.

3. The bone implant of claim 1 , wherein the UCAM or the extract thereof is formulated as a sheet, a pulverized powder, or a homogenate.

4. The bone implant of claim 1 , wherein the UCAM or the extract thereof comprises a pharmaceutically acceptable diluent, excipient, or carrier.

5. The bone implant of claim 1 , wherein the UCAM or the extract thereof is formulated as a solution, suspension, paste, ointment, oil, emulsion, microemulsion, cream, lotion, gel, or any combination thereof.

6. The bone implant of claim 1 , wherein the UCAM or the extract thereof is a sheet.

7. The bone implant of claim 1 , wherein the UCAM or the extract thereof is coated onto an outside surface of the bone implant.

8. The bone implant of claim 1 , wherein the UCAM or the extract thereof is configured to elute from the bone implant.

9. The bone implant of claim 6 , wherein the sheet is wrapped around an osteolytic bone or osteolytic joint.

10. The bone implant of claim 1 , wherein the bone implant is formulated for injection at arthritic joints of an individual.

11. The bone implant of claim 1 , wherein the bone implant is further formulated for administration by an implant or by a patch.

12. The bone implant of claim 1 , wherein the UCAM or the extract thereof inhibits undesired osteoclast differentiation.

13. The bone implant of claim 12 , wherein the undesired osteoclast differentiation causes arthritis, osteoporosis, bone tumor, Paget's disease, alveolar bone degradation, or any combination thereof.

14. The bone implant of claim 13 , wherein the arthritis comprises osteoarthritis, rheumatoid arthritis, psoriatic arthritis, or any combination thereof.

15. The bone implant of claim 1 , wherein the UCAM or the extract thereof inhibits osteoclast activity.

16. The bone implant of claim 15 , wherein the osteoclast activity causes arthritis, osteoporosis, bone tumor, Paget's disease, alveolar bone degradation, or any combination thereof.

17. The bone implant of claim 1 , wherein the UCAM or extract thereof is water-soluble.

18. The bone implant of claim 1 , wherein the bone implant is formed or formulated as a bone stent, an osseointegrated implant, a micronized powder, a sheet, or an orthopedic prosthesis.

19. The bone implant of claim 1 , wherein UCAM or the extract thereof comprises at least 0.2 μg/ml of HC-HA/PTX3 complex.

20. The bone implant of claim 1 , wherein UCAM or the extract thereof comprises at least 1.0 μg/ml of HC-HA/PTX3 complex.

21. The bone implant of claim 1 , wherein UCAM or the extract thereof comprises at least 5.0 μg/ml of HC-HA/PTX3 complex.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FUNDING IV TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0200 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FINANCIAL TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0165 →
SECURITY INTEREST Recorded Jun 7, 2024
From: BIOTISSUE HOLDINGS INC.; BIOTISSUE OCULAR INC.; BIOTISSUE SURGICAL INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 067666/0235 →
CHANGE OF NAME Recorded May 10, 2023
From: TISSUETECH, INC.
To: BIOTISSUE HOLDINGS INC.
Reel/Frame 063600/0798 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - REVOLVING LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 060116/0468 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - TERM LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 060116/0413 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2017
From: TSENG, SCHEFFER; TAN, EK KIA; HE, HUA
To: TISSUETECH, INC.
Reel/Frame 042294/0446 →
Continuity (4)
Continuation 15348736 · Nov 10, 2016
Continuation 14004992
Provisional Application 61480281 · Apr 28, 2011
Related Publication 20170239389A1 · Aug 24, 2017
References Cited (400)
US 3598122A · Zaffaroni · 1971 [cited by applicant]
US 3598123A · Zaffaroni · 1971 [cited by applicant]
US 3710795A · Higuchi et al. · 1973 [cited by applicant]
US 3731683A · Zaffaroni · 1973 [cited by applicant]
US 3742951A · Zaffaroni · 1973 [cited by applicant]
US 3814097A · Ganderton et al. · 1974 [cited by applicant]
US 3921636A · Zaffaroni · 1975 [cited by applicant]
US 3972995A · Tsuk et al. · 1976 [cited by applicant]
US 3993072A · Zaffaroni · 1976 [cited by applicant]
US 3993073A · Zaffaroni · 1976 [cited by applicant]
US 3996934A · Zaffaroni · 1976 [cited by applicant]
US 4031894A · Urquhart et al. · 1977 [cited by applicant]
US 4060084A · Chandrasekaran et al. · 1977 [cited by applicant]
US 4069307A · Higuchi et al. · 1978 [cited by applicant]
US 4077407A · Theeuwes et al. · 1978 [cited by applicant]
US 4201211A · Chandrasekaran et al. · 1980 [cited by applicant]
US 4230105A · Harwood · 1980 [cited by applicant]
US 4292299A · Suzuki et al. · 1981 [cited by applicant]
US 4292303A · Keith et al. · 1981 [cited by applicant]
US 4305502A · Gregory et al. · 1981 [cited by applicant]
US 4327725A · Cortese et al. · 1982 [cited by applicant]
US 4347841A · Benyo et al. · 1982 [cited by applicant]
US 4476116A · Anik · 1984 [cited by applicant]
US 4624848A · Lee · 1986 [cited by applicant]
US 4871549A · Ueda et al. · 1989 [cited by applicant]
US 4968509A · Radebaugh et al. · 1990 [cited by applicant]
US 5011692A · Fujioka et al. · 1991 [cited by applicant]
US 5017381A · Maruyama et al. · 1991 [cited by applicant]
US 5033252A · Carter · 1991 [cited by applicant]
US 5052558A · Carter · 1991 [cited by applicant]
US 5093487A · Brown et al. · 1992 [cited by applicant]
US 5116817A · Anik · 1992 [cited by applicant]
US 5229135A · Philippon et al. · 1993 [cited by applicant]
US 5260068A · Chen · 1993 [cited by applicant]
US 5260069A · Chen · 1993 [cited by applicant]
US 5323907A · Kalvelage · 1994 [cited by applicant]
US 5336168A · Sibalis · 1994 [cited by applicant]
US 5436135A · Tayot et al. · 1995 [cited by applicant]
US 5437287A · Phillips et al. · 1995 [cited by applicant]
US 5456923A · Nakamichi et al. · 1995 [cited by applicant]
US 5461140A · Heller et al. · 1995 [cited by applicant]
US 5508040A · Chen · 1996 [cited by applicant]
US 5516527A · Curatolo · 1996 [cited by applicant]
US 5554593A · Nakaya et al. · 1996 [cited by applicant]
US 5567441A · Chen · 1996 [cited by applicant]
US 5622721A · Dansereau et al. · 1997 [cited by applicant]
US 5665378A · Davis et al. · 1997 [cited by applicant]
US 5686105A · Kelm et al. · 1997 [cited by applicant]
US 5700410A · Nakamichi et al. · 1997 [cited by applicant]
US 5837280A · Kenealy et al. · 1998 [cited by applicant]
US 5837284A · Mehta et al. · 1998 [cited by applicant]
US 5840329A · Bai · 1998 [cited by applicant]
US 5869090A · Rosenbaum · 1999 [cited by applicant]
US 5932545A · Henkin et al. · 1999 [cited by applicant]
US 5948766A · Milan et al. · 1999 [cited by applicant]
US 5977175A · Lin · 1999 [cited by applicant]
US 6046160A · Obi-Tabot · 2000 [cited by applicant]
US 6152142A · Tseng · 2000 [cited by applicant]
US 6203755B1 · Odland · 2001 [cited by applicant]
US 6326019B1 · Tseng · 2001 [cited by applicant]
US 6328765B1 · Hardwick et al. · 2001 [cited by applicant]
US 6391452B1 · Antonsen et al. · 2002 [cited by applicant]
US 6465014B1 · Moroni et al. · 2002 [cited by applicant]
US 6521179B1 · Girardot et al. · 2003 [cited by applicant]
US 6573249B2 · Lezdey et al. · 2003 [cited by applicant]
US 6632648B1 · Kampinga et al. · 2003 [cited by applicant]
US 6923983B2 · Morgan et al. · 2005 [cited by applicant]
US 6929801B2 · Klose et al. · 2005 [cited by applicant]
US 6932983B1 · Straub et al. · 2005 [cited by applicant]
US 6946144B1 · Jordan · 2005 [cited by applicant]
US 7494802B2 · Tseng et al. · 2009 [cited by applicant]
US 8071135B2 · Liu et al. · 2011 [cited by applicant]
US 8093365B2 · Wisniewski et al. · 2012 [cited by applicant]
US 8105634B2 · Liu et al. · 2012 [cited by applicant]
US 8153162B2 · Tseng et al. · 2012 [cited by applicant]
US 8182840B2 · Tseng et al. · 2012 [cited by applicant]
US 8182841B2 · Tseng et al. · 2012 [cited by applicant]
US 8187639B2 · Tseng et al. · 2012 [cited by applicant]
US 8323701B2 · Daniel et al. · 2012 [cited by applicant]
US 8372437B2 · Daniel · 2013 [cited by applicant]
US 8372438B2 · Daniel et al. · 2013 [cited by applicant]
US 8372439B2 · Daniel et al. · 2013 [cited by applicant]
US 8409626B2 · Daniel et al. · 2013 [cited by applicant]
US 8420126B2 · Tseng et al. · 2013 [cited by applicant]
US 8440235B2 · Tseng et al. · 2013 [cited by applicant]
US 8455009B2 · Tseng et al. · 2013 [cited by applicant]
US 8460714B2 · Tseng et al. · 2013 [cited by applicant]
US 8460715B2 · Daniel · 2013 [cited by applicant]
US 8460716B2 · Daniel · 2013 [cited by applicant]
US 8597687B2 · Daniel · 2013 [cited by applicant]
US 8623421B2 · Daniel · 2014 [cited by applicant]
US 8642092B2 · Daniel et al. · 2014 [cited by applicant]
US 8703207B2 · Daniel et al. · 2014 [cited by applicant]
US 8840665B2 · Young et al. · 2014 [cited by applicant]
US 8932805B1 · Brahm · 2015 [cited by applicant]
US 8961617B2 · Young · 2015 [cited by applicant]
US 8980630B2 · Woodbury et al. · 2015 [cited by applicant]
US 9084767B2 · Daniel et al. · 2015 [cited by applicant]
US 9161954B2 · Tseng et al. · 2015 [cited by applicant]
US 9161955B2 · Tseng et al. · 2015 [cited by applicant]
US 9161956B2 · Tseng et al. · 2015 [cited by applicant]
US 9162011B2 · Stilwell et al. · 2015 [cited by applicant]
US 9175066B2 · Tseng et al. · 2015 [cited by applicant]
US 9180145B2 · Brown et al. · 2015 [cited by applicant]
US 9198939B2 · Tseng et al. · 2015 [cited by applicant]
US 9265801B2 · Daniel · 2016 [cited by applicant]
US 9272003B2 · Daniel et al. · 2016 [cited by applicant]
US 9463207B2 · Daniel · 2016 [cited by applicant]
US 9498327B1 · Brahm · 2016 [cited by applicant]
US 9526770B2 · Tseng et al. · 2016 [cited by applicant]
US 9662355B2 · Koob et al. · 2017 [cited by applicant]
US 9682044B2 · Tseng et al. · 2017 [cited by applicant]
US 9694109B1 · Brahm · 2017 [cited by applicant]
US 9795639B1 · Brahm · 2017 [cited by applicant]
US 9801975B2 · Stilwell et al. · 2017 [cited by applicant]
US 9801976B2 · Stilwell et al. · 2017 [cited by applicant]
US 9803176B2 · Patel et al. · 2017 [cited by applicant]
US 9814746B2 · Werber et al. · 2017 [cited by applicant]
US 9821013B2 · McFetridge et al. · 2017 [cited by applicant]
US 9827293B2 · Koob et al. · 2017 [cited by applicant]
US 9913466B2 · Chang et al. · 2018 [cited by applicant]
US 9919078B1 · Brahm · 2018 [cited by applicant]
US 9920301B2 · Taghizadeh · 2018 [cited by applicant]
US 9944900B2 · Gage et al. · 2018 [cited by applicant]
US 9956248B2 · Tom et al. · 2018 [cited by applicant]
US 10039793B2 · Brown et al. · 2018 [cited by applicant]
US 10066202B2 · Woodbury et al. · 2018 [cited by applicant]
US 10105399B2 · Edinger et al. · 2018 [cited by applicant]
US 10220059B2 · Kihm et al. · 2019 [cited by applicant]
US 10232085B2 · Morse et al. · 2019 [cited by applicant]
US 10258456B2 · Morita et al. · 2019 [cited by applicant]
US 10258650B2 · Tom et al. · 2019 [cited by applicant]
US 10265344B2 · Tom et al. · 2019 [cited by applicant]
US 10272116B2 · Tom et al. · 2019 [cited by applicant]
US 10314688B2 · Shepard et al. · 2019 [cited by applicant]
US 10568914B1 · Brahm · 2020 [cited by applicant]
US 10576104B2 · Tom et al. · 2020 [cited by applicant]
US 10583219B1 · Brahm · 2020 [cited by applicant]
US 10610545B2 · Aberman · 2020 [cited by applicant]
US 10646519B2 · Tom et al. · 2020 [cited by applicant]
US 10688220B2 · Hopkinson et al. · 2020 [cited by applicant]
US 20030064093A1 · Jordan · 2003 [cited by applicant]
US 20030180181A1 · Greib et al. · 2003 [cited by applicant]
US 20040043026A1 · Tuan et al. · 2004 [cited by applicant]
US 20040048796A1 · Hariri et al. · 2004 [cited by applicant]
US 20040057938A1 · Ghinelli · 2004 [cited by applicant]
US 20040126323A1 · Shevchuk et al. · 2004 [cited by applicant]
US 20040180822A1 · Grafton · 2004 [cited by examiner]
US 20050064391A1 · Segal et al. · 2005 [cited by applicant]
US 20060078993A1 · Phan et al. · 2006 [cited by applicant]
US 20070048292A1 · Morita et al. · 2007 [cited by applicant]
US 20070071740A1 · Tseng · 2007 [cited by examiner]
US 20070202189A1 · Ahlfors et al. · 2007 [cited by applicant]
US 20080050814A1 · Allickson · 2008 [cited by applicant]
US 20080069895A1 · Liu et al. · 2008 [cited by applicant]
US 20080131522A1 · Liu et al. · 2008 [cited by applicant]
US 20080181935A1 · Bhatia et al. · 2008 [cited by applicant]
US 20080241211A1 · Han et al. · 2008 [cited by applicant]
US 20090130162A2 · Pathak et al. · 2009 [cited by applicant]
US 20090226499A1 · Wisniewski · 2009 [cited by examiner]
US 20100047214A1 · Abramson et al. · 2010 [cited by applicant]
US 20100272782A1 · Owens et al. · 2010 [cited by applicant]
US 20110212158A1 · Tom et al. · 2011 [cited by applicant]
US 20110256202A1 · Tom et al. · 2011 [cited by applicant]
US 20110307059A1 · Young et al. · 2011 [cited by applicant]
US 20110311491A1 · Edinger et al. · 2011 [cited by applicant]
US 20120010708A1 · Young et al. · 2012 [cited by applicant]
US 20120010727A1 · Young et al. · 2012 [cited by applicant]
US 20120020933A1 · Young et al. · 2012 [cited by applicant]
US 20120035743A1 · Young et al. · 2012 [cited by applicant]
US 20120035744A1 · Young et al. · 2012 [cited by applicant]
US 20120114712A1 · Liu et al. · 2012 [cited by applicant]
US 20120141595A1 · Tseng et al. · 2012 [cited by applicant]
US 20120263731A1 · Fraunhofer et al. · 2012 [cited by applicant]
US 20120294910A1 · Daniel et al. · 2012 [cited by applicant]
US 20130129836A1 · Daniel et al. · 2013 [cited by applicant]
US 20130156863A1 · Tseng et al. · 2013 [cited by applicant]
US 20130197665A1 · Daniel et al. · 2013 [cited by applicant]
US 20130209524A1 · Young · 2013 [cited by applicant]
US 20130211502A1 · Young · 2013 [cited by applicant]
US 20130211504A1 · Young · 2013 [cited by applicant]
US 20130211511A1 · Young · 2013 [cited by applicant]
US 20130218274A1 · Spencer et al. · 2013 [cited by applicant]
US 20130236506A1 · Young · 2013 [cited by applicant]
US 20130238100A1 · Young · 2013 [cited by applicant]
US 20130289724A1 · Young · 2013 [cited by applicant]
US 20130344162A1 · Morse et al. · 2013 [cited by applicant]
US 20130344163A1 · Tseng et al. · 2013 [cited by applicant]
US 20140050788A1 · Daniel et al. · 2014 [cited by applicant]
US 20140052247A1 · Daniel et al. · 2014 [cited by applicant]
US 20140052274A1 · Koob et al. · 2014 [cited by applicant]
US 20140106447A1 · Brown et al. · 2014 [cited by applicant]
US 20140255496A1 · Daniel et al. · 2014 [cited by applicant]
US 20140255508A1 · Morse et al. · 2014 [cited by applicant]
US 20140271776A1 · Vines et al. · 2014 [cited by applicant]
US 20140294777A1 · Tom et al. · 2014 [cited by applicant]
US 20140294780A1 · McFetridge et al. · 2014 [cited by applicant]
US 20140302162A1 · Morse et al. · 2014 [cited by applicant]
US 20140343688A1 · Morse et al. · 2014 [cited by applicant]
US 20150017255A1 · Koob et al. · 2015 [cited by applicant]
US 20150086634A1 · Koob et al. · 2015 [cited by applicant]
US 20150110850A1 · Daniel · 2015 [cited by applicant]
US 20150182661A1 · Daniel · 2015 [cited by applicant]
US 20150216912A1 · Koob · 2015 [cited by applicant]
US 20150250829A1 · Daniel et al. · 2015 [cited by applicant]
US 20150320906A1 · Broussard et al. · 2015 [cited by applicant]
US 20150328264A1 · Lucey et al. · 2015 [cited by applicant]
US 20150335686A1 · Spencer et al. · 2015 [cited by applicant]
US 20160067287A1 · McQueen et al. · 2016 [cited by applicant]
US 20160082152A1 · Brahm · 2016 [cited by applicant]
US 20160095931A1 · Tseng et al. · 2016 [cited by applicant]
US 20160106785A1 · Tseng et al. · 2016 [cited by applicant]
US 20160129049A1 · Tseng et al. · 2016 [cited by applicant]
US 20160129050A1 · Tseng et al. · 2016 [cited by applicant]
US 20160129051A1 · Tseng et al. · 2016 [cited by applicant]
US 20160151424A1 · Tseng et al. · 2016 [cited by applicant]
US 20160184368A1 · Tseng et al. · 2016 [cited by applicant]
US 20160303171A1 · Tseng et al. · 2016 [cited by applicant]
US 20160324902A1 · Tseng et al. · 2016 [cited by applicant]
US 20160346332A1 · Spencer et al. · 2016 [cited by applicant]
US 20170027993A1 · Ichim · 2017 [cited by applicant]
US 20170072102A1 · Tseng et al. · 2017 [cited by applicant]
US 20170203004A1 · Murphy et al. · 2017 [cited by applicant]
US 20170260500A1 · Goodman et al. · 2017 [cited by applicant]
US 20170326182A1 · Tseng et al. · 2017 [cited by applicant]
US 20170368105A1 · Sinclair et al. · 2017 [cited by applicant]
US 20180008649A1 · Aberman et al. · 2018 [cited by applicant]
US 20180017577A1 · Franco · 2018 [cited by applicant]
US 20180055622A1 · Tokish et al. · 2018 [cited by applicant]
US 20180059109A1 · Hsuan et al. · 2018 [cited by applicant]
US 20180110900A1 · Korenfeld · 2018 [cited by applicant]
US 20180112184A1 · Kim et al. · 2018 [cited by applicant]
US 20180117121A1 · Koob et al. · 2018 [cited by applicant]
US 20180119093A1 · Kukharchuk et al. · 2018 [cited by applicant]
US 20180126036A1 · Early · 2018 [cited by applicant]
US 20180127721A1 · Phan · 2018 [cited by applicant]
US 20180133261A1 · Herzberg et al. · 2018 [cited by applicant]
US 20180140641A1 · Harrell · 2018 [cited by applicant]
US 20180163177A1 · Lo et al. · 2018 [cited by applicant]
US 20180177716A1 · Noh et al. · 2018 [cited by applicant]
US 20180177989A1 · Prentice · 2018 [cited by applicant]
US 20180221418A1 · Daniel et al. · 2018 [cited by applicant]
US 20180256648A9 · Meiron et al. · 2018 [cited by applicant]
US 20180264049A1 · Wagner et al. · 2018 [cited by applicant]
US 20180271914A1 · Steed et al. · 2018 [cited by applicant]
US 20180271917A1 · Fu · 2018 [cited by applicant]
US 20180338998A1 · Petrucci · 2018 [cited by applicant]
US 20180338999A1 · Brown et al. · 2018 [cited by applicant]
US 20180344777A1 · Harris et al. · 2018 [cited by applicant]
US 20180344900A9 · Brown et al. · 2018 [cited by applicant]
US 20180346874A1 · Harris et al. · 2018 [cited by applicant]
US 20180360886A1 · Tom et al. · 2018 [cited by applicant]
US 20180362920A1 · Guo · 2018 [cited by applicant]
US 20180362923A1 · Guo · 2018 [cited by applicant]
US 20180362932A1 · Guo · 2018 [cited by applicant]
US 20190001021A1 · Tseng · 2019 [cited by applicant]
US 20190040355A1 · Woodbury et al. · 2019 [cited by applicant]
US 20190046585A1 · Morse et al. · 2019 [cited by applicant]
US 20190054125A1 · Kihm · 2019 [cited by applicant]
US 20190070335A1 · Karagianis · 2019 [cited by applicant]
US 20190083548A1 · Morse et al. · 2019 [cited by applicant]
US 20190105351A9 · Kramer et al. · 2019 [cited by applicant]
US 20190105352A9 · Brown et al. · 2019 [cited by applicant]
US 20190127702A1 · Kerkis et al. · 2019 [cited by applicant]
US 20190134100A1 · Cao et al. · 2019 [cited by applicant]
US 20190134265A1 · Semler et al. · 2019 [cited by applicant]
US 20190141987A1 · Patel et al. · 2019 [cited by applicant]
US 20190175789A1 · Morse et al. · 2019 [cited by applicant]
US 20190177684A1 · Ha et al. · 2019 [cited by applicant]
US 20200069739A1 · Tom et al. · 2020 [cited by applicant]
US 20200077987A1 · Harrell · 2020 [cited by applicant]
US 20200129563A1 · Flower · 2020 [cited by applicant]
US 20200147144A1 · White et al. · 2020 [cited by applicant]
US 20200147145A1 · Steed et al. · 2020 [cited by applicant]
US 20200155613A1 · Beaudry et al. · 2020 [cited by applicant]
US 20200179566A1 · Liu et al. · 2020 [cited by applicant]
US 20210283190A1 · Koob et al. · 2021 [cited by applicant]
US 20220016180A1 · Danilkovitch et al. · 2022 [cited by applicant]
US 20220125855A1 · Morse et al. · 2022 [cited by applicant]
US 20230310512A1 · Tseng et al. · 2023 [cited by applicant]
US 20230364155A1 · Tseng · 2023 [cited by applicant]
CN 1193515A · 1998 [cited by applicant]
CN 1203794A · 1999 [cited by applicant]
CN 1903073A · 2007 [cited by applicant]
CN 103874762A · 2014 [cited by applicant]
EP 1604695A1 · 2005 [cited by applicant]
JP 74043153B · 1974 [cited by applicant]
JP H01256967A · 1989 [cited by applicant]
KR 20010098716A · 2001 [cited by applicant]
WO WO03077794A2 · 2003 [cited by applicant]
WO WO03097809A2 · 2003 [cited by applicant]
WO WO2004026244A2 · 2004 [cited by applicant]
WO WO2004060388A1 · 2004 [cited by applicant]
WO WO2006094247A2 · 2006 [cited by applicant]
WO WO2007011693A2 · 2007 [cited by applicant]
WO WO2007038686A2 · 2007 [cited by applicant]
WO WO2007071048A1 · 2007 [cited by applicant]
WO WO2009032773A2 · 2009 [cited by applicant]
WO WO2011031489A2 · 2011 [cited by applicant]
WO WO2011132087A1 · 2011 [cited by applicant]
WO WO2012149574A1 · 2012 [cited by applicant]
WO WO2017132503A1 · 2017 [cited by applicant]
WO WO2020097251A1 · 2020 [cited by applicant]
WO WO2020257626A1 · 2020 [cited by applicant]
WO WO2022093725A1 · 2022 [cited by applicant]
Greggi, Chiara et al. PTX3 Effects on Osteogenic Differentiation in Osteoporosis: An In Vitro Study. International Journal of Molecular Science. 22, 5944. (Year: 2021). [cited by examiner]
Allred et al. A novel ELISA for measuring CD36 protein in human adipose tissue. J Lipid Res 2(2):408-415 (2011). [cited by applicant]
Co-pending U.S. Appl. No. 15/879,042, filed Jan. 24, 2018. [cited by applicant]
Ericsson et al. Chapter 17: Protein extraction from solid tissue. Methods Mol Biol. 675:307-312 (2011). [cited by applicant]
Fiorito et al. Chapter 14: Surgical Management of Diabetic Foot Ulcers. Surgical Wound Healing and Management (pp. 128-142) (2012). [cited by applicant]
Hall et al. Liquid Extraction Surface Analysis Mass Spectrometry Method for Identifying the Presence and Severity of Nonalcoholic Fatty Liver Disease. Anal. Chem. 89(9):5161-5170 (2017). [cited by applicant]
He et al. Suppression of activation and induction of apoptosis in RAW264.7 cells by amniotic membrane extract. Invest Ophthalmol. Vis. Sci. 49:4468-4475 (2008). [cited by applicant]
Li et al. Reversal of myofibroblasts by amniotic membrane stromal extract. J Cell Physiol. 215(3):657-664 (2008). [cited by applicant]
PCT/US2017/015325 International Search Report and Written Opinion dated Jun. 9, 2017. [cited by applicant]
U.S. Appl. No. 13/322,896 Office Action dated Sep. 6, 2017. [cited by applicant]
U.S. Appl. No. 13/704,231 Office Action dated Aug. 16, 2017. [cited by applicant]
U.S. Appl. No. 13/802,204 Office Action dated Sep. 7, 2017. [cited by applicant]
U.S. Appl. No. 14/848,143 Office Action dated Jun. 21, 2017. [cited by applicant]
U.S. Appl. No. 14/886,946 Office Action dated Jan. 8, 2018. [cited by applicant]
U.S. Appl. No. 14/996,051 Office Action dated Jul. 24, 2017. [cited by applicant]
Ahmed et al. Expression and localization of alphavbeta6 integrin in extraplacental fetal membranes: possible role in human parturition. Mol Hum Reprod 10(3):173-179 (2004). [cited by applicant]
Bae et al. Characterization of the Promoter Region of the Human Transforming Growth Factor-β Type II Receptor Gene. J. Biol. Chem. 270(49):29460-29468 (1995). [cited by applicant]
Bhutto et al. Localization of Collagen XVIII and the Endostatin Portion of Collagen XVIII in Ages Human Control Eyes and Eyes with Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 45(5):1544-1552 (2004). [cited by applicant]
Border et al. Transforming Growth Factor-β in Disease: The Dark Side of Tissue Repair. J. Clin. Invest. 90:1-7 (1992). [cited by applicant]
Chen et al. Functions of hyaluronan in wound repair. Wound Rep Reg 7:79-89 (1999). [cited by applicant]
Chen et al. Recombinant Adenovirus Coexpressing Covalent Peptide/MHC Class II Complex and B7-1: In Vitro and In Vivo Activation of Myelin Basic Protein-Specific T Cells. J. Immunol. 167:1297-1305 (2001). [cited by applicant]
Colon et al. Transfer of Inter-α-inhibitor Heavy Chains to Hyaluronan by Surface-linked Hyaluronan-TSG-6 Complexes. J. Biol. Chem. 2009. 284:2320-2331. [cited by applicant]
Cooke et al. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. J Wound Care 23(10):465-474 (2014). [cited by applicant]
Day et al. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends in Immunology 26(12):637-643 (2005). [cited by applicant]
Derynk et al. TGF-β receptor signaling, Biochem. Biophys. Acta. 1333:F105-F150 (1997). [cited by applicant]
English Translation of JP74043153B (App. S45-107284) (9 pgs.) (Pub. Nov. 19, 1974). [cited by applicant]
Fortunato et al. Interleukin-10 and transforming growth factor-62 inhibit amniochorion tumor necrosis factor-α production by contrasting mechanisms of action: Therapeutic implications in prematurity. Am. J. Obstet. Gyn… [cited by applicant]
Fortunato et al. Interleukin-10 inhibition of interleukin-6 in human amniochorionic membrane: Transcriptional regulation. Am. J. Obstet. Gynecol. 175:1057-1065 (1996). [cited by applicant]
Fortunato et al. The effect of transforming growth factor and interleukin-10 on interleukin-8 release by human amniochorion may regulate histologic chorioamnionitis. Am. J. Obstet. Gynecol. 179(3):794-799 (1998). [cited by applicant]
Fries et al. Inter-alpha-inhibitor, hyaluronan and inflammation. Acta Biochim Polonica 50(3):735-742 (2003). [cited by applicant]
GABBIANI. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200:500-503 (2003). [cited by applicant]
GRANDE. Role of Transforming Growth Factor-β in Tissue Injury and Repair. Proc. Soc. Exp. Biol. Med. 214:27-40 (1997). [cited by applicant]
Guo. Carbopol® Polymers for Pharmaceutical Drug Delivery Applications. Drug Delivery Technology 3(6):1-4 (2003). [cited by applicant]
Hales et al. TGF-β-1 induces lens cells to accumulate a-smooth muscle actin, a marker for subcapsular cataracts. Curr. Eye Res. 13:885-890 (1994). [cited by applicant]
Hanada et al. Regulation of cytokine signaling and inflammation. Cytokine & Growth Factor Reviews 13(4-5):413-421 (2002). [cited by applicant]
Hao et al. Identification of Antiangiogenic and Antiinflammatory Proteins in Human Amniotic Membrane. Cornea 19(3):348-352 (2000). [cited by applicant]
Hatano et al. Transplantation of amniotic membrane and limbal autograft in the treatment of recurrent pterygium. Clinical Ophthalmology 50(6):1101-1104 (1996) (English Abstract). [cited by applicant]
He et al. A simplified system for generating recombinant adenoviruses. PNAS USA 95:2509-2514 (1998). [cited by applicant]
He et al. Biochemical Characterization and Function of Complexes formed by Hyaluronan and the Heavy Chains of Inter-α-inhibitor (HC-HA) Purified from Extracts of Human Amniotic Membrane. J Biol Chem 284(30):20136-20146 … [cited by applicant]
He et al. Inhibition of Proliferation and Epithelial Mesenchymal Transition via Wnt and TGF-β Signaling Pathway in an in vitro Cell Culture Based-PVR Model by HC-HA/PTX3 Purified from Amniotic Membrane. The Association … [cited by applicant]
He et al. Role of Hyaluronan, Inter-Alpha-Trypsin Inhibitor, and TSG-6 Complex in Amniotic Membrane in Inhibiting TFG-Beta Transcription. ARVO Annual Meeting Abstract. Investigative Ophthalmology & Visual Science 47:599… [cited by applicant]
Heiligenhaus et al. Improvement of HSV-1 Necrotizing Keratitis with Amniotic Membrane Transplantation Invest Ophthalmol Vis Sci 42(9):1969-1974 (2001). [cited by applicant]
Hilmy et al. Physical and chemical properties of freeze-dried amnio-chorion membranes sterilized by y irradiation. Atom Indonesia 13(2):1-3 (1987) Abstract only. [cited by applicant]
Hirashima et al. Inter-alpha-trypsin inhibitor is concentrated in the pericellular environment of mouse granulosa cells through hyaluronan-binding. Eur J Obstet Gynecol Reprod Biol. 73:79-84 (1997). [cited by applicant]
Hori. Amniotic Membrane Transplantation and Immune Reaction. Folia Ophthalmologica Japonica 56(9):722-727 (2005) (English Abstract). [cited by applicant]
Howes et al. Receptor for Advanced Glycation End Products and Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 45(10):3713-3720 (2004). [cited by applicant]
Jadin et al. Characterization of a Novel Recombinant Hyaluronan Binding Protein for Tissue Hyaluronan Detection. Journal of Histochemistry & Cytochemistry 62(9):672-683 (2014). [cited by applicant]
Jester et al. Corneal Stromal Wound Healing in Refractive Surgery: the Role of Myofibroblasts. Prog. Retin. Eye Res. 18(3):311-356 (1999). [cited by applicant]
Jester et al. Induction of α-Smooth Muscle Actin Expression and Myofibroblast Transformation in Cultured Cornea Keratocytes. Cornea 15(5):505-516 (1996). [cited by applicant]
Keelan et al. Activin A Exerts both Pro- and -Anti-inflammatory Effects on Human Term Gestational Tissues. Placenta 21:38-43 (2000). [cited by applicant]
Kobayashi et al. Identification of structural domains in inter-alpha-trypsin inhibitor involved in calcium oxalate crystallization. Kidney Int 53:1727-1735 (1998). [cited by applicant]
Kopp et al. Abrogation of Transforming Growth Factor-beta Signaling by SMAD7 Inhibits Collagen Gel Contraction of Human Dermal Fibroblasts. J. Biol. Chem. 280(22):21570-21576 (2005). [cited by applicant]
Kuriyan et al. A potential novel therapy for PVR: HC-HA/PTX3, an active matrix component of amniotic membrane, inhibits proliferation of rabbit RPE cells and is non-toxic intravitreally. The Association for Research in … [cited by applicant]
Kuriyan et al. HC-HA/PTX3, an active matrix component of amniotic membrane, inhibits proliferation and epithelial mesenchymal transition of RPE cells: a potential novel therapy for PVR. The Association for Research in V… [cited by applicant]
Kuznetsova et al. The N-terminal module of thrombospondin-1 interacts with the link domain of TSG-6 and enhances its covalent association with the heavy chains of inter-alpha-trypsin inhibitor. J Biol Chem 280:30899-309… [cited by applicant]
Lawrence. Transforming Growth Factor-β: a general review. Eur. Cytokine Netw. 7:363-374 (1996). [cited by applicant]
Lee et al. An Agarose Gel Electrophoretic Method for Analysis of Hyaluronan Molecular Weight Distribution. Anal. Biochem. 219:278-287 (1994). [cited by applicant]
Li et al. An Experimental Study of the Effects of Human Amniotic Membrane on Human Retinal Pigment Epithelial Cell Proliferation in vitro. Acta Acadamiae Medicinae Militaris Tertia 25(5):407-409 (2003) (English Abstract… [cited by applicant]
Lieberman et al. Pharmaceutical Dosage Forms. 2 Ed. 1:209-214 (1990). [cited by applicant]
Liu et al. Biocompatibility and stability of disulfide-crosslinked hyaluronan films. Biomaterials 26(23):4737-4746 (2005). [cited by applicant]
Logan et al. Decorin Attenuates Gliotic Scar Formation in the Rat Cerebral Hemisphere. Exp. Neurol. 159:504-510 (1999). [cited by applicant]
Marek et al. TGF-β—(transforming growth factor-β) in chronic inflammatory conditions—a new diagnostic and prognostic marker? Med. Sci. Monitl. 8(7):RA145-RA151 (2002). [cited by applicant]
Massague et al. Controlling TGF-β signaling. Genes and Development 14:627-644 (2000). [cited by applicant]
Milner et al. TSG-6: a multifunctional protein associated with inflammation. J. Cell Sci. 116(10):1863-1873 (2003). [cited by applicant]
Moller-Pedersen et al. Neutralizing antibody to TGF-β modulates stromal fibrosis but not regression of photoablative effect following PRK. Curr. Eye Res. 17:736-747 (1998). [cited by applicant]
Monteleone et al. SMAD7 in TGF-β-mediated negative regulation of gut inflammation. Trends in Immunology 25(10):513-517 (2004). [cited by applicant]
Mukhopadhyay et al. Two distinct populations of tumor necrosis factor-stimulated gene-6 protein in the extracellular matrix of expanded mouse cumulus cell-oocyte complexes. Archives of Biochemistry and Biophysics 394(2)… [cited by applicant]
Na et al. Analysis of Human Amniotic Membrane Components as Proteinase Inhibitors for Development of Therapeutic Agent for Recalcitrant Keratitis. Trophoblast Res. 13:453-466 (1999). [cited by applicant]
Nakao et al. SMAD7: a new key player in TGF-b-associated disease. Trends in Molecular Medicine 8(8):361-363 (2002). [cited by applicant]
Neumann et al. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-KB activation and cytokine expression. FEBS Ltrs. 453:283-287(1999). [cited by applicant]
Ochsner et al. Decreased expression of tumor necrosis factor-alpha-stimulated gene 6 in cumulus cells of the cyclooxygenase2 and EP2 null mice. Endocrinology 144:1008-1019 (2003). [cited by applicant]
Oikawa et al. Inhibition of Angiogenesis by 15-Deoxyspergualin. J. Antibiotics 44(9):1033-1035 (1991). [cited by applicant]
PCT/US2006/37906 International Preliminary Report on Patentability dated Apr. 1, 2008. [cited by applicant]
PCT/US2006/37906 International Search Report and Written Opinion dated Jul. 11, 2007. [cited by applicant]
PCT/US2010/032452 International Preliminary Report on Patentability dated Oct. 25, 2011. [cited by applicant]
PCT/US2010/032452 International Search Report dated Dec. 27, 2010. [cited by applicant]
PCT/US2010/46675 International Preliminary Report on Patentability dated Feb. 28, 2012. [cited by applicant]
PCT/US2010/46675 International Search Report and Written Opinion dated May 30, 2011. [cited by applicant]
PCT/US2011/042679 International Preliminary Report on Patentability dated Jan. 8, 2013. [cited by applicant]
PCT/US2011/042679 International Search Report and Written Opinion dated Mar. 9, 2012. [cited by applicant]
PCT/US2012/035678 International Preliminary Report on Patentability dated Oct. 29, 2013. [cited by applicant]
PCT/US2012/035678 International Search Report and Written Opinion dated Oct. 1, 2012. [cited by applicant]
PCT/US2015/059142 International Preliminary Report on Patentability dated May 18, 2017. [cited by applicant]
Petraglia et al. Inhibin and Activin in Human Fetal Membranes: Evidence of a Local Effect on Prostaglandin Release. J. Clin. Endocrinol. Metab. 77(2):542-548 (1993). [cited by applicant]
Relucenti et al. Cumulus oophorus extracellular matrix in the human oocyte: a role for adhesive proteins. Ital J Anat Embryol 110(2 Supp 1):219-224 (2005). [cited by applicant]
Riley et al. Production of inhibin forms by the fetal membranes, decidua, placenta and fetus at parturition. Hum. Reprod. 15:578-583 (2000). [cited by applicant]
Romero et al. The natural interleukin-1 receptor antagonist in the fetal, maternal, and amniotic fluid compartments: The effect of gestational age, fetal gender, and intrauterine infection. Am. J. Obstet. Gynecol. 171:9… [cited by applicant]
Ronnov-Jessen et al. Induction of α-Smooth Muscle Actin by Transforming Growth Factor-β1 in Quiescent Human Breast Gland Fibroblasts. Lab. Invest. 68:696-707 (1993). [cited by applicant]
Rovere et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 96(13):4300-4306 (2000). [cited by applicant]
Rugg et al., Characterization of complexes formed between TSG-6 and inter-alpha-inhibitor that act as intermediates in the covalent transfer of heavy chains onto hyaluronan. J Biol Chem 280(27):25674-25686 (2005). [cited by applicant]
Saltzman. Drug Administration and Drug Effectiveness. Chapter 2. Drug Delivery—Engineering Principles for Drug Therapy. Oxford Press. p. 9-19 (2001). [cited by applicant]
Salustri et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 131:1577-1586 (2004). [cited by applicant]
Sanggaard et al, The transfer of heavy chains from bikunin proteins to hyaluronan requires both TSG-6 and HC2. J Biol Chem 283(27):18530-18537 (2008). [cited by applicant]
Serini et al. The Fibronectin Domain ED-A Is Crucial for Myofibroblastic Phenotype Induction by Transforming Growth Factor-β1. J. Cell. Biol. 142:873-881 (1998). [cited by applicant]
Shah et al. Control of scarring in adult wounds by neutralising antibody to transforming growth factor β. Lancet 339:213-214 (1992). [cited by applicant]